Nasus Pharma Says FDA Cleared IND Application For NS002 Intranasal Epinephrine Powder In Anaphylaxis; Plans Pivotal Study In Q4 2026, Topline Data In Q1 2027
Share
Why It Matters
Nasus Pharma got FDA approval to test a new allergy medicine powder. Now watch if their testing study starts on time and works well.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.